Cargando…

Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used for treating EGFR-mutated lung cancer, and osimertinib is effective in cases that acquired T790M mutations after treatment with the first- and second-generation EGFR-TKIs. However, no study has evaluated its safety and...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakao, Akira, Hiranuma, Osamu, Uchino, Junji, Sakaguchi, Chikara, Araya, Tomoyuki, Hiraoka, Noriya, Ishizuka, Tamotsu, Takeda, Takayuki, Kawasaki, Masayuki, Goto, Yasuhiro, Imai, Hisao, Hattori, Noboru, Nakatomi, Keita, Uramoto, Hidetaka, Uryu, Kiyoaki, Fukuda, Minoru, Uchida, Yasuki, Yokoyama, Toshihide, Akai, Masaya, Mio, Tadashi, Nagashima, Seiji, Chihara, Yusuke, Tamiya, Nobuyo, Kaneko, Yoshiko, Mouri, Takako, Yamada, Tadaaki, Yoshimura, Kenichi, Fujita, Masaki, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356339/
https://www.ncbi.nlm.nih.gov/pubmed/32517152
http://dx.doi.org/10.3390/jcm9061762
_version_ 1783558477215432704
author Nakao, Akira
Hiranuma, Osamu
Uchino, Junji
Sakaguchi, Chikara
Araya, Tomoyuki
Hiraoka, Noriya
Ishizuka, Tamotsu
Takeda, Takayuki
Kawasaki, Masayuki
Goto, Yasuhiro
Imai, Hisao
Hattori, Noboru
Nakatomi, Keita
Uramoto, Hidetaka
Uryu, Kiyoaki
Fukuda, Minoru
Uchida, Yasuki
Yokoyama, Toshihide
Akai, Masaya
Mio, Tadashi
Nagashima, Seiji
Chihara, Yusuke
Tamiya, Nobuyo
Kaneko, Yoshiko
Mouri, Takako
Yamada, Tadaaki
Yoshimura, Kenichi
Fujita, Masaki
Takayama, Koichi
author_facet Nakao, Akira
Hiranuma, Osamu
Uchino, Junji
Sakaguchi, Chikara
Araya, Tomoyuki
Hiraoka, Noriya
Ishizuka, Tamotsu
Takeda, Takayuki
Kawasaki, Masayuki
Goto, Yasuhiro
Imai, Hisao
Hattori, Noboru
Nakatomi, Keita
Uramoto, Hidetaka
Uryu, Kiyoaki
Fukuda, Minoru
Uchida, Yasuki
Yokoyama, Toshihide
Akai, Masaya
Mio, Tadashi
Nagashima, Seiji
Chihara, Yusuke
Tamiya, Nobuyo
Kaneko, Yoshiko
Mouri, Takako
Yamada, Tadaaki
Yoshimura, Kenichi
Fujita, Masaki
Takayama, Koichi
author_sort Nakao, Akira
collection PubMed
description Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used for treating EGFR-mutated lung cancer, and osimertinib is effective in cases that acquired T790M mutations after treatment with the first- and second-generation EGFR-TKIs. However, no study has evaluated its safety and efficacy in older patients. This phase II trial (jRCTs071180002) evaluated osimertinib in T790M mutation-positive Japanese patients who were ≥75 years old and had experienced relapse or progression after previous EGFR-TKI treatment. Our previous report that enrolled 36 patients showed the overall response rate (58.3%) and disease control rate (97.2%), while this report describes the results for the progression-free survival (PFS), overall survival (OS), and safety analyses. The median PFS was 11.9 months (95% confidence interval (CI): 7.9–17.5), and the median OS was 22.0 months (95% CI: 16.0 months–not reached). The most frequent adverse events were anemia/hypoalbuminemia (27 patients, 75.0%), thrombocytopenia (21 patients, 58.3%), and paronychia/anorexia/diarrhea/neutropenia (15 patients, 41.7%). Pneumonitis was observed in four patients (11.1%), including two patients (5.6%) with Grade 3–4 pneumonitis. These results suggest that osimertinib was relatively safe and effective for non-small cell lung cancer that acquired T790M mutations after previous EGFR-TKI treatment, even among patients who were ≥75 years old.
format Online
Article
Text
id pubmed-7356339
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73563392020-07-30 Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment Nakao, Akira Hiranuma, Osamu Uchino, Junji Sakaguchi, Chikara Araya, Tomoyuki Hiraoka, Noriya Ishizuka, Tamotsu Takeda, Takayuki Kawasaki, Masayuki Goto, Yasuhiro Imai, Hisao Hattori, Noboru Nakatomi, Keita Uramoto, Hidetaka Uryu, Kiyoaki Fukuda, Minoru Uchida, Yasuki Yokoyama, Toshihide Akai, Masaya Mio, Tadashi Nagashima, Seiji Chihara, Yusuke Tamiya, Nobuyo Kaneko, Yoshiko Mouri, Takako Yamada, Tadaaki Yoshimura, Kenichi Fujita, Masaki Takayama, Koichi J Clin Med Article Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used for treating EGFR-mutated lung cancer, and osimertinib is effective in cases that acquired T790M mutations after treatment with the first- and second-generation EGFR-TKIs. However, no study has evaluated its safety and efficacy in older patients. This phase II trial (jRCTs071180002) evaluated osimertinib in T790M mutation-positive Japanese patients who were ≥75 years old and had experienced relapse or progression after previous EGFR-TKI treatment. Our previous report that enrolled 36 patients showed the overall response rate (58.3%) and disease control rate (97.2%), while this report describes the results for the progression-free survival (PFS), overall survival (OS), and safety analyses. The median PFS was 11.9 months (95% confidence interval (CI): 7.9–17.5), and the median OS was 22.0 months (95% CI: 16.0 months–not reached). The most frequent adverse events were anemia/hypoalbuminemia (27 patients, 75.0%), thrombocytopenia (21 patients, 58.3%), and paronychia/anorexia/diarrhea/neutropenia (15 patients, 41.7%). Pneumonitis was observed in four patients (11.1%), including two patients (5.6%) with Grade 3–4 pneumonitis. These results suggest that osimertinib was relatively safe and effective for non-small cell lung cancer that acquired T790M mutations after previous EGFR-TKI treatment, even among patients who were ≥75 years old. MDPI 2020-06-05 /pmc/articles/PMC7356339/ /pubmed/32517152 http://dx.doi.org/10.3390/jcm9061762 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nakao, Akira
Hiranuma, Osamu
Uchino, Junji
Sakaguchi, Chikara
Araya, Tomoyuki
Hiraoka, Noriya
Ishizuka, Tamotsu
Takeda, Takayuki
Kawasaki, Masayuki
Goto, Yasuhiro
Imai, Hisao
Hattori, Noboru
Nakatomi, Keita
Uramoto, Hidetaka
Uryu, Kiyoaki
Fukuda, Minoru
Uchida, Yasuki
Yokoyama, Toshihide
Akai, Masaya
Mio, Tadashi
Nagashima, Seiji
Chihara, Yusuke
Tamiya, Nobuyo
Kaneko, Yoshiko
Mouri, Takako
Yamada, Tadaaki
Yoshimura, Kenichi
Fujita, Masaki
Takayama, Koichi
Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment
title Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment
title_full Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment
title_fullStr Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment
title_full_unstemmed Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment
title_short Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment
title_sort final results from a phase ii trial of osimertinib for elderly patients with epidermal growth factor receptor t790m-positive non-small cell lung cancer that progressed during previous treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356339/
https://www.ncbi.nlm.nih.gov/pubmed/32517152
http://dx.doi.org/10.3390/jcm9061762
work_keys_str_mv AT nakaoakira finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT hiranumaosamu finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT uchinojunji finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT sakaguchichikara finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT arayatomoyuki finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT hiraokanoriya finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT ishizukatamotsu finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT takedatakayuki finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT kawasakimasayuki finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT gotoyasuhiro finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT imaihisao finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT hattorinoboru finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT nakatomikeita finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT uramotohidetaka finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT uryukiyoaki finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT fukudaminoru finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT uchidayasuki finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT yokoyamatoshihide finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT akaimasaya finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT miotadashi finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT nagashimaseiji finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT chiharayusuke finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT tamiyanobuyo finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT kanekoyoshiko finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT mouritakako finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT yamadatadaaki finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT yoshimurakenichi finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT fujitamasaki finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment
AT takayamakoichi finalresultsfromaphaseiitrialofosimertinibforelderlypatientswithepidermalgrowthfactorreceptort790mpositivenonsmallcelllungcancerthatprogressedduringprevioustreatment